Loading clinical trials...
Loading clinical trials...
A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen
Conditions
Interventions
VAL401
Start Date
October 1, 2016
Primary Completion Date
September 1, 2017
Completion Date
September 1, 2017
Last Updated
October 15, 2018
NCT06696768
NCT04704661
NCT05691465
NCT05039801
NCT05198830
NCT04657068
Lead Sponsor
ValiSeek Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions